Patents Examined by Nizal Chandrakumar
  • 2,3-dihydroquinazolin-4(1H)-one derivatives for use in the treatment of viral infections
    Patent number: 9675615
    Abstract: Use of 2,3-dihydroquinazolin-4(1H)-one cyclic derivatives of formula (I) for the treatment of infection with viruses entering cells by endocytosis, especially filovirus such as Ebolavirus.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: June 13, 2017
    Assignees: Commissariat a l'Energie Atomique et aux Energies Alternatives, The Board of Regents of the University of Texas System
    Inventors: Daniel Gillet, Julien Barbier, Robert Davey, Jean-Christophe Cintrat, Romain Noel
  • Substituted 3-hydroxy-?-lactones from epoxides
    Patent number: 9676743
    Abstract: Catalysts and methods for the carbonylation of epoxides to substituted 3-hydroxy-?-lactones and ?-lactones are disclosed.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: June 13, 2017
    Assignee: Cornell University
    Inventors: Geoffrey W. Coates, John W. Kramer
  • Assays and methods of treatment relating to vitamin D insufficiency
    Patent number: 9671414
    Abstract: Described herein are assays directed to determining the level of bioavailable or free vitamin D in a blood sample in a subject. The values determined for bioavailable or free vitamin D indicate whether the subject suffers from insufficient levels of vitamin D. Also described herein are methods of treatment for vitamin D insufficiency.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: June 6, 2017
    Assignees: Beth Israel Deaconess Medical Center, Inc., The General Hospital Corporation
    Inventors: Ravi Thadhani, S. Ananth Karumanchi, Anders Hayden Berg, Ishir Bhan
  • Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders
    Patent number: 9669035
    Abstract: The present invention relates to combinations of phosphodiesterase 2 (PDE2) inhibitors with inhibitors of phosphodiesterase 10 (PDE10). In particular, the invention relates to combinations of 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives which have been found to inhibit phosphodiesterase 2 (PDE2), with inhibitors of phosphodiesterase 10 (PDE10). Particular PDE10 inhibitors are selected from the group of MP-10, PQ-10, TP-10, papaverine, and the compounds disclosed in WO 2011/051324 and in WO 2011/110545.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: June 6, 2017
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Antonius Adrianus Hendrikus Petrus Megens, Xavier Jean Michel Langlois, José Ignacio Andrés-Gil
  • Small molecule modifiers of the Hec1-Nek2 interaction in G2/M
    Patent number: 9670197
    Abstract: Certain embodiments of the present invention provide selected compounds having a molecular structure according to Formula 1: In Formula 1, Z is —CO—, —SO—, or —SO2—; Ar is phenyl, heteroaryl, or heterocycloalkyl; Het is heteroaryl; R is R?, X, or NR1R2; R? is R3, or OR3; R? is R4, or OR4; R1 and R2 are each independently H, alkyl, or acyl; R3 is H, heteroaryl, or alkyl; R4 is H, heteroaryl, or CnH2n+1 (n>2); and X is F, Br, I, CN, or NO2. In some embodiments, compounds having a molecular structure according to Formula 1 have the property of inhibiting a growth of a cell line selected from HeLa and MB468 with a sub-micromolar IC50.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: June 6, 2017
    Assignee: The Regents of the University of California
    Inventors: Wen-Hwa Lee, Jiewen Zhu, Chun-Mei Hu
  • Method for producing substituted anthranilic acid derivatives
    Patent number: 9670182
    Abstract: The present invention relates to a process for preparing substituted anthranilic acid derivatives of the formula (I) in which R1, R2, R3 and R4 are each as defined in the description, by conversion of compounds of the general formula (IV) in the presence of a palladium catalyst and carbon monoxide. The present invention likewise relates to compounds of the general formula (IV).
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: June 6, 2017
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Thomas Himmler, Sergii Pazenok, Frank Volz, Norbert Lui
  • Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof
    Patent number: 9657030
    Abstract: The present disclosure provides processes for the N-dealkylation of tertiary amines and the use of transition metal catalysts to prepare tertiary N-allyl amine derivatives and secondary amine derivatives thereof. The tertiary amines can be alkaloids and, more particularly, the tertiary amines can be opioids. In specific embodiments, the present disclosure provides methods for use in processes for the synthesis of naloxone and naltrexone from oripavine.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: May 23, 2017
    Assignee: Rhodes Technologies
    Inventors: Joshua Robert Giguere, Keith Edward McCarthy, Helge Alfred Reisch, Sergio Sandoval, Jake Larry Stymiest
  • Transition-metal-free N-arylation of tertiary amines using arynes
    Patent number: 9650329
    Abstract: The present invention relates to transition-metal-free process for the synthesis of tertiary arylamines comprises coupling reaction between arynes and N,N-dimethyl aniline compounds in presence of 18-crown-6, KF and THF.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: May 16, 2017
    Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Akkattu Thankappan Biju, Sachin Suresh Bhojgude, Trinadh Kaicharla
  • Use of 15-benzylidence-14-deoxy-11, 12 -dehyroandrographolide derivative in manufacture of medicaments for protecting liver and anti-hepatitis C virus
    Patent number: 9636324
    Abstract: Disclosed is use of andrographolide derivative as shown by general formula 1 in manufacture of medicaments for anti-hepatitis C virus, and preventing and treating immunological liver damage caused by virus infection and different chemical liver damage.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: May 2, 2017
    Assignee: Zhengzhou University
    Inventors: Guifu Dai, Jing Zhao, Haiwei Xu, Huanfei Liu, Zhenwei Wu, Di Wu, Jian Wu, Hongmin Liu
  • Sweetener
    Patent number: 9635879
    Abstract: A low calorie sweetener composition with sweetness synergy, providing a reduction in off-taste and a desirable temporal profile. The sweetener composition comprises allulose, fructose and sucralose. In a preferred embodiment, the sweetener composition comprises allulose in an amount of at least about 45%, fructose in an amount of at least about 20%, and sucralose in an amount of at least about 0.01% by weight relative to the total weight of allulose, fructose and sucralose in the composition. The sweetener composition is suitable for use as a substitute for high calorie sugars. The sweetener composition is for use in food and beverage products, pharmaceutical products, nutritional product and cosmetic products.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 2, 2017
    Assignee: TATE & LYLE INGREDIENTS AMERICAS LLC
    Inventors: Ryan D. Woodyer, Jason C. Cohen, John R. Bridges
  • Genetic signature of vulnerability to inhibitors of base excision repair (BER) in cancer
    Patent number: 9637798
    Abstract: The invention relates to the identification of genetic signatures and expression profiles that are a part of the Base Excision Repair (BER) pathway, a major DNA repair pathway that modifies base lesions. In one embodiment, the present invention provides a method of determining responsiveness of treatment by BER inhibitors for malignant glioma by determining the presence of a low level of expression of Apex 1, a low level of expression of Apex 2, and a high level of expression of MPG.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: May 2, 2017
    Assignees: Dignity Health, The Translational Genomics Research Institute
    Inventors: Shwetal V. Mehta, Michael E. Berens, Harshil Dineshkumar Dhruv
  • TRPV1 antagonists including dihydroxy substituent and uses thereof
    Patent number: 9630959
    Abstract: The disclosure relates to Compounds of Formula (I) and pharmaceutically acceptable derivatives thereof, where R1, R4, R8, R9, and m are as defined herein, compositions comprising an effective amount of a Compound of Formula (I) or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, pain associated with osteoarthritis, osteoarthritis, UI, an ulcer, IBD, and IBS, comprising administering to an animal in need thereof an effective amount of a Compound of Formula (I) or a pharmaceutically acceptable derivative thereof.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: April 25, 2017
    Assignees: Purdue Pharma L.P., Shionogi & Co., Ltd.
    Inventors: Shigeru Ando, Noriyuki Kurose, Laykea Tafesse
  • Small compounds targeting TACC3
    Patent number: 9630953
    Abstract: The present invention provides a small compound targeting at TACC3. The present invention further provides a drug, particularly, an anticancer agent, comprising the small compound targeting at TACC3. A compound represented by the general formula (I) or a pharmaceutically acceptable salt, solvate, or ester derivative thereof binds to TACC3 and inhibits cell growth. Thus, these compounds can be used as drugs, particularly, anticancer agents.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: April 25, 2017
    Assignee: JAPANESE FOUNDATION FOR CANCER RESEARCH
    Inventors: Ryoji Yao, Hiroyuki Osada, Yasumitsu Kondoh
  • Cysteamine prodrugs, pharmaceutical compositions thereof, and methods of use
    Patent number: 9630917
    Abstract: Cysteamine prodrugs, pharmaceutical compositions comprising the cysteamine prodrugs, and methods of using cysteamine prodrugs and pharmaceutical compositions thereof for treating eye, kidney, liver, metabolic, and neurological disorders such as cystinosis, cystinuria, non-alcoholic steatohepatitis, Batten disease, Leigh syndrome, and Huntington's disease.
    Type: Grant
    Filed: September 19, 2015
    Date of Patent: April 25, 2017
    Inventor: Mark Quang Nguyen
  • Quinolinyl modulators of ROR?t
    Patent number: 9624225
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: April 18, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kristi A. Leonard, Kent Barbay, James P. Edwards, Kevin D. Kreutter, David A. Kummer, Umar Maharoof, Rachel Nishimura, Maud Urbanski, Hariharan Venkatesan, Aihua Wang, Ronald L. Wolin, Craig R. Woods, Xiaohua Xue, Maxwell D. Cummings, Kelly McClure, Virginia Tanis
  • Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof
    Patent number: 9624232
    Abstract: The present disclosure provides processes for the N-dealkylation of tertiary amines and the use of transition metal catalysts to prepare tertiary N-allyl amine derivatives and secondary amine derivatives thereof. The tertiary amines can be alkaloids and, more particularly, the tertiary amines can be opioids. In specific embodiments, the present disclosure provides methods for use in processes for the synthesis of naloxone and naltrexone from oripavine.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: April 18, 2017
    Assignee: Rhodes Technologies
    Inventors: Joshua Robert Giguere, Keith Edward McCarthy, Helge Alfred Reisch, Sergio Sandoval, Jake Larry Stymiest
  • Compounds for treating spinal muscular atrophy
    Patent number: 9617268
    Abstract: Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. In a specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN2 into mRNA that is transcribed from the SMN2 gene. In another specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 into mRNA that is transcribed from the SMN1 gene. In yet another embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 and SMN2 into mRNA that is transcribed from the SMN1 and SMN2 genes, respectively.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: April 11, 2017
    Assignees: PTC Therapeutics, Inc., F. Hoffmann-La Roche AG
    Inventors: Matthew G. Woll, Guangming Chen, Soongyu Choi, Amal Dakka, Song Huang, Gary Mitchell Karp, Chang-Sun Lee, Chunshi Li, Jana Narasimhan, Nikolai Naryshkin, Sergey Paushkin, Hongyan Qi, Anthony A. Turpoff, Marla L. Weetall, Ellen Welch, Tianle Yang, Nanjing Zhang, Xiaoyan Zhang, Xin Zhao, Emmanuel Pinard, Hasane Ratni
  • Herbicidal isoxazolo[5,4-b]pyridines
    Patent number: 9609870
    Abstract: The invention relates to isoxazolo[5,4-b]pyridine compounds of formula I, to the agriculturally useful salts of isoxazolo[5,4-b]pyridine compounds of formula I, and to their use as herbicides.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: April 4, 2017
    Assignee: BASF SE
    Inventors: Anna Aleksandra Michrowska-Pianowska, Julia Major, Johannes Hutzler, Trevor William Newton, Richard Roger Evans, Klaus Kreuz, Klaus Grossmann, Dschun Song, Anja Simon, Matthias Witschel, William Karl Moberg, Liliana Parra Rapado, Tao Qu, Frank Stelzer, Helmut Kraus, Thomas Seitz, Andree van der Kloet, Ruediger Reingruber
  • Solid pharmaceutical composition
    Patent number: 9603804
    Abstract: [Problem] To provide a solid pharmaceutical composition which contains a compound represented by general formula (1) or a salt thereof and suppresses decomposition of said compound or salt thereof, and a production method of said solid pharmaceutical composition. [Solution] This solid pharmaceutical composition contains a compound represented by general formula (1) or a salt thereof, a cellulosic excipient, and an acidic substance of pH 4.0 or less.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: March 28, 2017
    Assignee: KYORIN PHARMACEUTICAL CO., LTD.
    Inventors: Hiroshi Uchida, Masataka Hanada
  • Treatment of pancreatic and related cancers with 5-acyl-6,7-Dihydrothieno[3,2-C]pyridines
    Patent number: 9597320
    Abstract: Methods for inhibiting the growth of pancreatic cancer cells or other cancer cells driven by Sonic hedgehog are disclosed.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: March 21, 2017
    Assignees: Memorial Sloan-Kettering Cancer Center, The Rockefeller University
    Inventors: Marilyn D. Resh, Joseph Fraser Glickman, Elissaveta Petrova, Ouathek Ouerfelli